SmithRx Expands Autoimmune Program with Stelara Biosimilars, Projects $14.5M Annual Savings
核心洞察
SmithRx (搜索) announces major expansion of Connect 360 Autoimmune Program, introducing Stelara biosimilars that offer over 95% savings compared to the original drug's $35,000 per fill list price.
The PBM forms strategic partnership with Costco Specialty Pharmacy (搜索) and strengthens ties with Mark Cuban Cost Plus Drugs (搜索) to provide $0 copay options for members accessing biosimilars.
Program expansion includes new low-cost Humira and Stelara biosimilar options specifically for pediatric patients, building on previous success that saw 90% of members transition to Humira biosimilar Yusimry.
In a significant move to reduce prescription drug costs, SmithRx (搜索), a transparent pharmacy benefits manager (PBM), has announced a major expansion of its Connect 360 Autoimmune Program. The expansion centers on the introduction of Stelara biosimilars, promising substantial cost savings for employers and patients managing various autoimmune conditions.
The initiative is projected to generate $14.5 million in annual savings for employer groups, with individual patients potentially saving up to $155,000 per year. These biosimilars will be offered at a fraction of Stelara's current list price of $35,000 per fill, representing over 95% in cost reduction.
Proven Track Record in Biosimilar Adoption
SmithRx (搜索) has already demonstrated success in biosimilar implementation through its Connect 360 program. "Our Connect 360 program was built because we saw a better way to generate real, tangible savings for our members and clients," explains Alan Pannier, SVP of Clinical Strategy at SmithRx. The company has achieved an impressive 90% transition rate of members to Yusimry, a Humira biosimilar, resulting in a 90% reduction in Humira-related spending for clients.
Enhanced Access Through Strategic Partnerships
The program's expansion includes a new partnership with Costco Specialty Pharmacy (搜索), complementing SmithRx (搜索)'s existing collaboration with Mark Cuban Cost Plus Drugs (搜索). Both partnerships aim to provide members with access to low-cost biosimilars, featuring $0 copays and free shipping options.
Pediatric Patient Support
A key component of the expansion is the introduction of specialized low-cost biosimilar options for pediatric patients under 18 years of age. This initiative ensures younger patients requiring Humira or Stelara treatments can access more affordable alternatives through Costco Specialty Pharmacy (搜索).
Clinical Impact and Accessibility
The expanded program particularly benefits patients with various autoimmune conditions, including plaque psoriasis (搜索), Crohn's Disease (搜索), ulcerative colitis (搜索), and psoriatic arthritis (搜索). By making these treatments more accessible, SmithRx (搜索) addresses a critical need in autoimmune disease management while maintaining clinical effectiveness through FDA-approved biosimilar alternatives.
The company's innovative approach combines technological solutions with personalized service, utilizing a drug pathways engine to connect patients with cost-effective treatment alternatives. This systematic approach has helped transform the perception of prescription benefits, demonstrating that effective medication management can be both affordable and straightforward.